Brief: Onxeo Announces New Preclinical Results On AsiDNA

Valerio Therapeutics SA

12/07/2018 07:21

July 12 (Reuters) - ONXEO SA  C4X.PA :
    * NEW PRECLINICAL RESULTS ON ONXEO'S ASIDNA™, FIRST-IN-CLASS
DNA
REPAIR INHIBITOR, POINT TO STRONG SYNERGY AND REVERSION OF TUMOR
RESISTANCE WHEN COMBINED TO PARP INHIBITORS
    * TOGETHER WITH FIRST ACTIVITY RESULTS OF DRIIV-1 STUDY OF
ASIDNA
EXPECTED IN Q4 2018
    * RESULTS POINT TO  ABILITY OF ASIDNA™ TO PREVENT OCCURRENCE
OF
RESISTANCE AND TO REVERSE ACQUIRED RESISTANCE OF TUMOR CELL
AFTER PARPI TREATMENTS

Source text for Eikon:  ID:nBw2gyYpBa 
Further company coverage:  C4X.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))